ANIP News and Press, ANI Pharmaceuticals Inc. From 11/01/21

Gainers: ABVC BioPharma (NASDAQ:ABVC) +250%, ANI Pharmaceuticals (NASDAQ:ANIP) +51%, Artelo Biosciences (NASDAQ:ARTL) +37%, Nutriband (NTRBW) +34%, Regencell Bioscience (NASDAQ:RGC) +15%. Losers: Centessa Pharmaceuticals (NASDAQ:CNTA) -19%, Mi...

ANI Pharmaceuticals (ANIP +46.1%) shares are sharply higher today after the company reported better than expected Q3 2021 earnings and was granted an expanded approval for its cortrophin gel. The company hit a 52-week high of $57.69 earlier in the morning. ANI also said its acquisition o...

After Alnylam Pharmaceuticals (NASDAQ:ANIP) suffered a loss of nearly 20% last week on the departure of company’s long-serving CEO John Maraganore, Oppenheimer has upgraded the stock expecting the shares to recover as the impact of the news wanes over time. The price tar...

ANI Pharmaceuticals (NASDAQ:ANIP): Q3 Non-GAAP EPS of $1.01 beats by $0.31; GAAP EPS of -$0.37 misses by $0.16. Revenue of $52.06M (-1.7% Y/Y) beats by $2.36M. Shares +5.40% PM. Press Release For further details see: ANI Pharmaceuticals EPS beats by $0.31, beats on revenue

The U.S. FDA has approved ANI Pharmaceuticals' (NASDAQ:ANIP) sNDA for Purified Cortrophin Gel for the treatment of certain chronic autoimmune disorders. The approval allows for the use of Cortrophin in conditions, including acute exacerbations of multiple sclerosis (MS) and rheumato...

-- Third quarter 2021 net revenues of $52.1 million; net loss of $4.4 million and diluted loss per share of ($0.37) -- -- Third quarter adjusted non-GAAP EBITDA of $16.6 million and adjusted non-GAAP diluted earnings per share of $1.01 -- -- FDA approves supplemental n...

-- Cortrophin Gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders -- -- Approval re-introduces much needed patient and physician choice into the U.S. repository corticotropin market -- -- Early Q1 ...

ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to announce Q3 earnings results on Monday, November 1st, before market open. The consensus EPS Estimate is $0.70 (-27.8% Y/Y) and the consensus Revenue Estimate is $49.7M (-6.2% Y/Y). Over the last 2 years, ANIP has beaten EPS estimates 50% of th...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2021 financial results on Monday, November 1, 2021. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Car...

The following slide deck was published by ANI Pharmaceuticals, Inc. in conjunction with this event. For further details see: ANI Pharmaceuticals (ANIP) Investor Presentation - Slideshow